{"entity":{"id":"nct07231458","kind":"trial","name":"A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies","aka":[],"tldr":"A phase 1 trial of ABX-001 run by Abalos Therapeutics GmbH, now recruiting.","summary":"A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies is a phase 1 interventional study registered as NCT07231458 by Abalos Therapeutics GmbH, with 27 participants planned, started 2025-10-14. Conditions recorded: Advanced Solid Tumors. Interventions recorded: ABX-001 and Pembrolizumab.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07231458","url":"https://clinicaltrials.gov/study/NCT07231458"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["abx-001"],"companies":["abalos-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07231458","phase":"1","setting":"A Phase I/Ib Open-Label Study of ABX-001 Administered With and Without the Anti-PD-1 Immune Checkpoint Inhibitor Pembrolizumab in Participants With Advanced Solid Tumors Who Are Beyond Standard of Care","sponsor":"Abalos Therapeutics GmbH","enrolled":27,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07231458/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"abx-001","kind":"drug","name":"ABX-001","route":"/drugs/abx-001/"}],"company":[{"id":"abalos-therapeutics","kind":"company","name":"Abalos Therapeutics","route":"/companies/abalos-therapeutics/"}]}}